Qiagen NV-Aktie mit leichten Kursgewinnen (40,955 €) |
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers |
QIAGEN N.V.: QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) |